Your browser doesn't support javascript.
loading
Macrophages-based immune-related risk score model for relapse prediction in stage I-III non-small cell lung cancer assessed by multiplex immunofluorescence.
Wu, Xiang-Rong; Peng, Hao-Xin; He, Miao; Zhong, Ran; Liu, Jun; Wen, Yao-Kai; Li, Cai-Chen; Li, Jian-Fu; Xiong, Shan; Yu, Tao; Zheng, Hong-Bo; Chen, Yan-Hui; He, Jian-Xing; Liang, Wen-Hua; Cai, Xiu-Yu.
Afiliação
  • Wu XR; Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Peng HX; Nanshan School, Guangzhou Medical University, Guangzhou, China.
  • He M; Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Zhong R; Nanshan School, Guangzhou Medical University, Guangzhou, China.
  • Liu J; Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Wen YK; Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Li CC; Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Li JF; School of Medicine, Tongji University, Shanghai, China.
  • Xiong S; Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China.
  • Yu T; Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Zheng HB; Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Chen YH; Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • He JX; Genecast Biotechnology Co., Ltd., Wuxi, China.
  • Liang WH; Genecast Biotechnology Co., Ltd., Wuxi, China.
  • Cai XY; Genecast Biotechnology Co., Ltd., Wuxi, China.
Transl Lung Cancer Res ; 11(4): 523-542, 2022 Apr.
Article em En | MEDLINE | ID: mdl-35529784
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Transl Lung Cancer Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Transl Lung Cancer Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China